Drug intelligence / Profile preview

citasoxacin

Development stage: Unknown
Lead developer: Hainan Hualong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Citasoxacin is a novel fluoroquinolone antibiotic developed by Hainan Hualong Pharmaceutical for the treatment of acute bacterial infections. It functions by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, which are essential enzymes for bacterial DNA replication, transcription, repair, and recombination. The drug has been evaluated in Phase 3 clinical trials in China, specifically comparing its efficacy and safety to levofloxacin in patients with acute respiratory tract infections (such as community-acquired pneumonia and acute bronchitis) and urinary tract infections (such as acute pyelonephritis and cystitis).

Other names: 希他沙星

Targets

DNA gyraseTopo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on citasoxacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on citasoxacin.

Explore the full profile